These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 9484879)
1. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment? Norrby SR J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879 [No Abstract] [Full Text] [Related]
2. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997]. Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540 [No Abstract] [Full Text] [Related]
3. The activity of grepafloxacin against respiratory pathogens in the UK. Wise R; Andrews JM J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870 [TBL] [Abstract][Full Text] [Related]
6. Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa. Sato A; Kitazawa H; Chida K; Hayakawa H; Iwata M Drugs; 1995; 49 Suppl 2():253-5. PubMed ID: 8549321 [No Abstract] [Full Text] [Related]
7. Grepafloxacin--a new fluoroquinolone. Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856 [No Abstract] [Full Text] [Related]
8. [Significant role of newer quinolone antimicrobials in respiratory tract infection: focused on sparfloxacin]. Jpn J Antibiot; 1994 Oct; 47(10):1241-58. PubMed ID: 7807686 [No Abstract] [Full Text] [Related]
9. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Forrest A; Chodosh S; Amantea MA; Collins DA; Schentag JJ J Antimicrob Chemother; 1997 Dec; 40 Suppl A():45-57. PubMed ID: 9484873 [TBL] [Abstract][Full Text] [Related]
13. [Use of new quinolones in respiratory infections]. Sanz Moreno J; Jiménez Rodríguez A Rev Clin Esp; 2000 Dec; 200(12):682-4. PubMed ID: 11234474 [No Abstract] [Full Text] [Related]
14. New fluoroquinolone antibiotics. Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769 [TBL] [Abstract][Full Text] [Related]
15. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections. Niki Y; Tamada S; Nakabayashi M; Soejima R Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385 [No Abstract] [Full Text] [Related]
16. [Effect of Baytril (Bay Vp 2674) on young turkeys with respiratory tract infections]. Braunius WW Tijdschr Diergeneeskd; 1987 May; 112(9):531-3. PubMed ID: 3603541 [TBL] [Abstract][Full Text] [Related]
17. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Lode H; Vogel F; Elies W Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425 [TBL] [Abstract][Full Text] [Related]
18. Activity of grepafloxacin against respiratory isolates of Streptococcus pneumoniae. Johnson AP; Warner M; Parsons T Eur J Clin Microbiol Infect Dis; 1997 Aug; 16(8):622-3. PubMed ID: 9323481 [No Abstract] [Full Text] [Related]
19. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351 [TBL] [Abstract][Full Text] [Related]
20. The fluoroquinolones after ciprofloxacin and ofloxacin. Hooper DC Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519 [No Abstract] [Full Text] [Related] [Next] [New Search]